This platform recognizes the real-world challenges of implementing tissue-based biomarker testing in pathology and provides practical tools to support this testing at diagnosis in prostate cancer.
Location
Baltimore, Maryland, USA
By the numbers
18 years of experience in anatomic pathology
Led PTEN immunohistochemistry testing in 5 clinical trials
>150 peer-reviewed publications focused on prostate cancer
This platform recognizes the real-world challenges of implementing tissue-based biomarker testing in pathology and provides practical tools to support this testing at diagnosis in prostate cancer.
About Dr Tamara Lotan
Dr Tamara Lotan is the Rose-Lee and Keith Reinhard Professor of Urologic Oncology at the Johns Hopkins University School of Medicine, where she also serves as Director of Research for the Brady Urological Institute. She is a urologic pathologist with a translational research focus on identifying tissue-based biomarkers that support precision diagnostics and prognosis in prostate cancer.
Dr Lotan leads a laboratory investigating molecular drivers of prostate cancer and health disparities. She also conducts separate research into renal oncogenesis, aligned with her interests in mechanistic target of rapamycin signaling. For over a decade, her research has included mechanistic and biomarker studies investigating phosphatase and tensin homolog (PTEN) and prostate cancer, particularly the use of immunohistochemistry to detect PTEN loss in primary disease. She also serves as co-investigator on initiatives supporting early research careers in pathology and maintains an active diagnostic practice focused on genitourinary tumors.
Her work has been widely published and has informed clinical practice and ongoing research into the biological underpinnings of prostate cancer.
Key areas of interest
- Immunohistochemistry for PTEN loss detection in primary prostate cancer
- Optimizing prostate biomarker and immunohistochemistry testing workflows
- Validating novel prognostic and predictive tissue-based biomarkers
Dr Tamara Lotan has been compensated by AstraZeneca for their time and expertise in contributing to this initiative.
Explore key pages
AKT, protein kinase B; mHSPC, metastatic hormone-sensitive prostate cancer; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog.
